Tharimmune (THAR) Competitors $1.55 -0.18 (-10.40%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$1.50 -0.05 (-2.90%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. NERV, RLMD, ATHA, FLGC, PRTG, BGXX, HOTH, CSCI, LSB, and BTAIShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Minerva Neurosciences (NERV), Relmada Therapeutics (RLMD), Athira Pharma (ATHA), Flora Growth (FLGC), Portage Biotech (PRTG), Bright Green (BGXX), Hoth Therapeutics (HOTH), COSCIENS Biopharma (CSCI), Lakeshore Biopharma (LSB), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Minerva Neurosciences Relmada Therapeutics Athira Pharma Flora Growth Portage Biotech Bright Green Hoth Therapeutics COSCIENS Biopharma Lakeshore Biopharma BioXcel Therapeutics Minerva Neurosciences (NASDAQ:NERV) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations. Which has more risk & volatility, NERV or THAR? Minerva Neurosciences has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Do insiders and institutionals have more ownership in NERV or THAR? 34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by insiders. Comparatively, 2.4% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, NERV or THAR? Tharimmune is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M$0.199.13TharimmuneN/AN/A-$9.32M-$9.74-0.16 Does the media refer more to NERV or THAR? In the previous week, Minerva Neurosciences and Minerva Neurosciences both had 2 articles in the media. Minerva Neurosciences' average media sentiment score of 0.94 beat Tharimmune's score of 0.60 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer NERV or THAR? Minerva Neurosciences received 345 more outperform votes than Tharimmune when rated by MarketBeat users. However, 100.00% of users gave Tharimmune an outperform vote while only 55.79% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34755.79% Underperform Votes27544.21% TharimmuneOutperform Votes2100.00% Underperform VotesNo Votes Is NERV or THAR more profitable? Minerva Neurosciences' return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% Tharimmune N/A -167.63%-130.18% Do analysts rate NERV or THAR? Minerva Neurosciences currently has a consensus target price of $5.00, suggesting a potential upside of 188.18%. Tharimmune has a consensus target price of $17.00, suggesting a potential upside of 996.77%. Given Tharimmune's stronger consensus rating and higher probable upside, analysts plainly believe Tharimmune is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryTharimmune beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.27M$6.85B$5.54B$7.93BDividend YieldN/A2.95%5.09%4.23%P/E Ratio-0.167.3222.6018.55Price / SalesN/A241.43400.01103.29Price / CashN/A65.8538.1834.62Price / Book0.016.486.774.25Net Income-$9.32M$143.41M$3.22B$248.18M7 Day Performance31.80%1.91%1.10%0.91%1 Month Performance20.16%4.28%2.48%2.58%1 Year Performance-72.63%-3.87%15.71%4.02% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune2.3054 of 5 stars$1.55-10.4%$17.00+996.8%-72.8%$3.27MN/A-0.162Upcoming EarningsNERVMinerva Neurosciences3.7898 of 5 stars$1.76-1.7%$5.00+184.1%-27.7%$12.31MN/A-4.009RLMDRelmada Therapeutics4.3625 of 5 stars$0.28-20.4%$4.25+1,396.0%-90.5%$11.85MN/A-0.1010Upcoming EarningsHigh Trading VolumeATHAAthira Pharma3.1999 of 5 stars$0.30+2.0%$13.83+4,511.1%-85.9%$11.71MN/A-0.1140Positive NewsFLGCFlora Growth3.3241 of 5 stars$0.60+2.2%$5.00+733.3%-64.9%$11.66M$59.51M-0.45280Positive NewsGap UpPRTGPortage Biotech0.8945 of 5 stars$11.03+2.4%N/A+133.9%$11.57MN/A-0.266Gap DownBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownHOTHHoth Therapeutics3.1657 of 5 stars$0.85-0.1%$4.00+370.0%-26.8%$11.21MN/A-0.644Short Interest ↓CSCICOSCIENS BiopharmaN/A$3.55+13.4%N/AN/A$11.15M$9.59M-0.3020Positive NewsLSBLakeshore Biopharma1.3932 of 5 stars$1.20-3.6%N/AN/A$11.13M$672.27M0.00773Short Interest ↓Gap UpBTAIBioXcel Therapeutics4.4452 of 5 stars$1.99+1.5%$42.60+2,040.7%-95.6%$10.92M$2.27M-0.0690Upcoming EarningsPositive NewsGap Up Related Companies and Tools Related Companies Minerva Neurosciences Competitors Relmada Therapeutics Competitors Athira Pharma Competitors Flora Growth Competitors Portage Biotech Competitors Bright Green Competitors Hoth Therapeutics Competitors COSCIENS Biopharma Competitors Lakeshore Biopharma Competitors BioXcel Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy THAR Stock Free THAR Stock Alerts